Emerging Therapies for the Management of Castration - Sensitive Prostate Cancer (On-Demand)Contains 6 Component(s), Includes Credits
Component Credit Type State/Medical Type Available Credits Earned Credits CME/CPE/CNE/Certificate of Participation Medical CME 1.00 0.00 CME/CPE/CNE/Certificate of Participation Medical CPE 1.00 0.00 CME/CPE/CNE/Certificate of Participation Medical CNE 1.00 0.00 CME/CPE/CNE/Certificate of Participation Medical Certificate of Participation 1.00 0.00
With recent drug approvals and updates to clinical practice guidelines, many oncology practitioners find it challenging to stay abreast of changing treatment recommendations for patients with mCSPC (metastatic castration-sensitive prostate cancer). This activity aims to provide guidance on the latest in optimal management of mCSPC for oncologists, urologists, oncology advanced practitioners and other members of the multidisciplinary cancer care team. The course will address challenges in optimal sequencing of care in mCSPC and will provide learners an opportunity to hear from experts regarding new research and clinical updates that can be translated into patient care strategies.
MRD Clinical Updates in Chronic Lymphocytic LeukemiaContains 3 Component(s)
A panel of hematologic malignancy experts provide important and practical information for the assessment of measurable residual disease (MRD) as part of routine clinical practice for their patients with chronic lymphocytic leukemia.
Big Data In Immuno-OncologyContains 7 Component(s)
Tune into sessions from the ACCC Big Data in IO Workshop, where expert faculty will delve into role of data in managing immune-related adverse events; applications of clinical trial and real-world data; the evolving integration of molecular data and patient-reported outcomes; and how new technologies will impact the future of data in immuno-oncology.
Multidisciplinary Advanced Cutaneous Squamous Cell Carcinoma Care (Two Part Series)Contains 6 Component(s)
The ACCC Multidisciplinary Advanced Cutaneous Squamous Cell Carcinoma (cSCC) Care education project series is designed to support the cancer care team in diagnosing, testing, and treating patients with advanced cSCC. The series will include webinars developed in conjunction with the multidisciplinary care team who have deep expertise in caring for patients with cSCC as well as high-risk non-melanoma skin cancers.
Multiple Myeloma Dispensing Models Webinar SeriesContains 12 Component(s)
The ACCC Multiple Myeloma Dispensing Models Webinar Series features six on-demand recordings that explore various dispensing models and effective practices in the care of patients with multiple myeloma.
Characterizing and Targeting Tumor Immune Microenvironment in FGFR-Mutated Bladder CancerContains 2 Component(s)
Webinar for TxSCO
Optimizing Outcomes for Patients with Urothelial Carcinoma: Recent Clinical UpdatesContains 5 Component(s), Includes Credits
Component Credit Type State/Medical Type Available Credits Earned Credits CME/CNE/Certificate of Participation Medical CME 0.75 0.00 CME/CNE/Certificate of Participation Medical CNE 0.75 0.00 CME/CNE/Certificate of Participation Medical Certificate of Participation 0.75 0.00
In a recent survey of community cancer care professionals conducted by the Association of Community Cancer Centers, bladder was reported to be one of the most commonly diagnosed cancers after breast, lung, prostate, and colorectal. For many community oncologists, it is hard to stay abreast of clinical updates and changing treatment recommendations across all tumor types. This initiative will summarize recent clinical data for immunotherapies and emerging targeted therapies used to treat advanced and metastatic urothelial carcinoma. Strategies for identification and management of treatment-related adverse events, as well as effective solutions for improving multidisciplinary care coordination, will also be covered.
Chronic Lymphocytic Leukemia: Up-to-Date Approaches to CareContains 4 Component(s)
Listen to current treatment approaches for patients with newly diagnosed through relapsed chronic lymphocytic leukemia (CLL) with an emphasis on the latest data from the 2018 ASH Annual Meeting.
|Access Date||Quiz Result||Score||Actions|